Medical imaging technology company Polarean Imaging plc (AIM: POLX) reported on Monday that its FDA-cleared XENOVIEW 3T Chest Coil has passed Philips' compatibility testing, confirming integration with Philips' latest 3T MRI platforms from early 2026.

Validation by Philips Medical Systems Nederland B.V. enables use of the coil on systems including the 3.0T MR 7700 and Ingenia Elition X, as well as eligible upgrade pathways. The milestone broadens access to advanced functional lung imaging and positions Polarean for accelerated clinical adoption and revenue growth following FDA clearance in 2024.

Expansion across Philips' global installed base strengthens commercial prospects by allowing clinical and research sites to incorporate non-invasive, quantitative lung function assessments into routine workflows. Polarean expects this integration to support wider deployment of its Xenon MRI technology and increase market penetration.

Polarean develops and commercialises MRI-based pulmonary imaging solutions, including XENOVIEW, the first FDA-approved hyperpolarised Xenon inhaled contrast agent. Founded in 2012, the company operates from Durham, North Carolina, and London.